In a report released yesterday, Mike Mayo from Wells Fargo maintained a Buy rating on PNC Financial (PNC – Research Report), with a price target of $235.00. The company’s shares closed ...

Evercore ISI analyst John Pancari reiterated a Buy rating on PNC Financial (PNC – Research Report) on January 17 and set a price target of $225.00. The company’s shares closed last Friday at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

The company has just one product on the market, Casgevy, which treats transfusion-dependent beta-thalassemia and sickle cell disease, two rare blood disorders. Casgevy has been on the market for a ...